| Authors: |
Levine YA; SetPoint Medical Corporation, Valencia, California, United States of America., Koopman FA; Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands., Faltys M; SetPoint Medical Corporation, Valencia, California, United States of America., Caravaca A; SetPoint Medical Corporation, Valencia, California, United States of America., Bendele A; Bolder BioPATH, Inc., Boulder, Colorado, United States of America., Zitnik R; SetPoint Medical Corporation, Valencia, California, United States of America., Vervoordeldonk MJ; Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands; Arthrogen BV, Amsterdam, the Netherlands., Tak PP; Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands; GlaxoSmithKline, Stevenage, United Kingdom; University of Cambridge, Cambridge, United Kingdom. |